**Background**
Allergic diseases, including allergic rhinitis, allergic conjunctivitis, and various allergic skin conditions, are characterized by hypersensitivity reactions mediated by the release of histamine and other inflammatory mediators. Histamine acts on several G protein-coupled receptors, among which the H1 receptor plays a pivotal role in inducing vasodilation, increased vascular permeability, and pruritus. Consequently, the development of high-affinity H1 receptor antagonists is essential for alleviating the symptoms associated with these allergic responses. In this context, we will introduce a potent benzimidazole derivative – Emedastine.
**Definition**
Emedastine is an orally active, selective, and high-affinity histamine H1 receptor antagonist with a Ki value of 1.3 nM.
**In Vitro and In Vivo Studies**
According to the Emedastine description, this compound is a benzimidazole derivative with potent antiallergic properties. Emedastine in vitro studies demonstrate its high selectivity for the H1 receptor compared to other histamine receptors, with Ki values of 49,067 nM for the H2 receptor and 12,430 nM for the H3 receptor. Furthermore, high concentrations of Emedastine (1 and 10 ng/ml) significantly inhibit the production of type 1 collagen in normal human dermal fibroblasts. Additionally, concentrations of ≥ 10 nM (tested at 1, 10, 100, and 1000 nM) inhibit CC chemokine-elicited eosinophil migration.
Regarding Emedastine In Vivo activity, the compound has shown significant efficacy in animal models. In male ICR mice (5-6 weeks old), oral pretreatment with Emedastine (0.1 and 0.3 mg/kg) 30 minutes before the injection of pruritogens significantly suppressed histamine-induced scratching, whereas a dose of 0.03 mg/kg did not. Moreover, oral pretreatment at 0.03, 0.1, and 0.3 mg/kg significantly inhibited scratching induced by substance P and leukotriene B. In guinea-pigs, Emedastine (0.3 mg/kg, p.o.) produced significant inhibition of passive peritoneal anaphylaxis. Furthermore, it inhibits histamine-induced contractions of the isolated ileum with an IC50 of 6.1 nM. For researchers seeking detailed Emedastine technical information, these results highlight its broad utility in studying allergic inflammation. In conclusion, Emedastine is a potent and selective H1 receptor antagonist effective in suppressing allergic reactions and pruritus.
Keywords
Emedastine, 87233-61-2, Histamine Receptor, orally, benzimidazole, antiallergic, allergic, rhinitis, skin, diseases, conjunctivitis, Inhibitor, inhibitor, inhibit
References
[1] Sharif NA, et al. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol. 1994 Winter;10(4):653-64.
[2] Murota H, et al. Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67.
[3] Andoh T, et al. Involvement of blockade of leukotriene B(4) action in anti-pruritic effects of emedastine in mice. Eur J Pharmacol. 2000 Oct 6;406(1):149-52.